Larry J. Copeland - Concepedia

Author

Larry J. Copeland

Also Known As

&NA;, C A Young, L Copeland, L J Copeland, L Wyatt, L. Copeland, L. J. COPELAND, L. J. Copeland, L.J. COPELAND, L.J. Copeland

359

Publications

14.6K

Citations

H-Index

138

Concepts

All Affiliations

The Ohio State University The University of Texas MD Anderson Cancer Center Anderson Hospital The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University Wexner Medical Center

About

Larry J. Copeland is an author at The Ohio State University specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	111	6.8K
2	Public Health	16	18	819
3	Health Sciences	11	11	1K
4	Social Sciences	2	2	273
5	Nursing	1	1	59

Larry J. Copeland

145

Publications

13.4K

Citations

H-Index

Page 1

	Year	Citations
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, New England Journal of Medicine	2006	2.6K
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, New England Journal of Medicine	2023	718
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, The Lancet Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicine	2017	656
Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients Heather Hampel, Wendy L. Frankel, Jenny Panescu, Cancer Research	2006	629
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Journal of Clinical Oncology	2019	461
Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial Maurie Markman, Pan Liu, Sharon P. Wilczynski, Journal of Clinical Oncology	2003	457
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology Robert J. Morgan, Deborah K. Armstrong, Ronald D. Alvarez, Journal of the National Comprehensive Cancer Network Cancer ManagementGynecologyPathologyGynecology OncologyCarcinoma	2016	318
HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients Carl Morrison, Vanna Zanagnolo, Nilsa C. Ramirez, Journal of Clinical Oncology	2006	253
Ovarian Cancer, Version 3.2012 Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Journal of the National Comprehensive Cancer Network	2012	196
HER-2/neu Amplification and Overexpression in Endometrial Carcinoma Chris D. Rolitsky, Karl S. Theil, Violeta R. McGaughy, International Journal of Gynecological Pathology	1999	176

Page 1